DUBLIN – Investors in Polyphor Ltd. have kept their faith in the company's first-in-class antibiotic therapy murepavadin (POL7080) by pumping in CHF40 million (US$39.8 million) in a largely internal round to fund a registration program in hospital acquired pneumonia (HAP) caused by Pseudomonas aeruginosa infection.